These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1878667)

  • 1. How do BMTs cure leukaemia? New directions.
    Prentice HG
    Bone Marrow Transplant; 1991; 7 Suppl 2():11-3. PubMed ID: 1878667
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
    Blaise D; Stoppa AM; Olive D; Brandely M; Tiberghien P; Attal M; Attal J; Reiffers J; Demeocq F; Pico JL
    Bone Marrow Transplant; 1991; 7 Suppl 2():146. PubMed ID: 1878687
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
    de Witte T; Preijers F; Schattenberg A
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
    [No Abstract]   [Full Text] [Related]  

  • 5. Cure after allogeneic bone marrow transplantation: chemo-radiotherapy and/or graft-versus-leukemia?
    Hagenbeek A; Martens AC; Schultz FW; van Bekkum DW
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():91-3. PubMed ID: 2390645
    [No Abstract]   [Full Text] [Related]  

  • 6. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The graft versus leukemia effect: possible mechanisms and clinical significance to the biologic therapy of leukemia.
    Sosman JA; Sondel PM
    Bone Marrow Transplant; 1991; 7 Suppl 1():33-7. PubMed ID: 2043883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antonio Raichs lecture. Graft versus host disease and the graft-against-leukemia reaction. Memorial lecture].
    Rozman C
    Sangre (Barc); 1990 Dec; 35(6):465-73. PubMed ID: 2087666
    [No Abstract]   [Full Text] [Related]  

  • 9. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
    Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
    Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
    [No Abstract]   [Full Text] [Related]  

  • 11. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cellular immunotherapy in chronic myeloid leukemia].
    Fernández MN
    Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
    [No Abstract]   [Full Text] [Related]  

  • 14. How do allogeneic bone marrow transplants cure leukaemia? The role of graft versus host disease.
    Powles R; Treleaven J; Millar J; Gordon-Smith EC; Tiley C; Findlay M; Teo C; Duncombe A; Robinson G
    Bone Marrow Transplant; 1991; 7 Suppl 2():9-10. PubMed ID: 1878737
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of minimal residual disease in acute leukemia--focus on immunotherapeutic options.
    Simonsson B; Nilsson BI; Rowe JM
    Leukemia; 1992 Nov; 6 Suppl 4():124-34. PubMed ID: 1279326
    [No Abstract]   [Full Text] [Related]  

  • 16. Graft-versus-leukaemia after bone marrow transplantation.
    Barret AJ
    Pediatr Med Chir; 1991; 13(1):9-13. PubMed ID: 2052462
    [No Abstract]   [Full Text] [Related]  

  • 17. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloimmune effects of bone marrow transplantation for leukaemia on the leukaemic diseases.
    Marmont AM
    Bone Marrow Transplant; 1991; 7 Suppl 2():2-3. PubMed ID: 1878696
    [No Abstract]   [Full Text] [Related]  

  • 19. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
    Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
    Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.
    Varadi G; Ackerstein A; Ben-Neriah S; Nagler A
    Bone Marrow Transplant; 1998 Jan; 21(1):93-6. PubMed ID: 9486502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.